Group effects EMA [Two-Stage / GS Designs]

posted by VStus – Poland, 2016-10-07 00:06 (3536 d 04:17 ago) – Posting: # 16701
Views: 46,174

Hi Helmut,

I have performed exercise on this dataset in R and have to support Mittyri: addition of more effects beyond group increases MSE and, therefore, CI:

anova(lm(log(response) ~ sequence + subject:sequence + period + treatment, data=data, na.action=na.exclude))["Residuals","Mean Sq"]
[1] 0.00075363
anova(lm(log(response) ~ sequence + subject:sequence + period + treatment + group, data=data, na.action=na.exclude))["Residuals","Mean Sq"]
[1] 0.00075363
anova(lm(log(response) ~ sequence + subject:sequence + period + treatment + group + period:group, data=data, na.action=na.exclude))["Residuals","Mean Sq"]
[1] 0.00078534


Due to my limited R knowledge, I cannot figure out how to add other effects recommended by FDA e.g. subject(sequence x group), but I'm afraid that at least in R, the more related effects - the wider confidence intervals...

Regards, VStus

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
111 visitors (0 registered, 111 guests [including 18 identified bots]).
Forum time: 04:23 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5